依维莫司在女性生殖器恶性肿瘤治疗中的应用

Application of Everolimus in the Treatment of the Malignant Tumors of Female Genital Organs

关键词:  mTOR抑制剂  依维莫司  子宫颈癌  卵巢癌  子宫内膜癌  临床应用

Key words:  mTOR inhibitor  everolimus  cervical cancer  ovarian cancer  endometrial cancer  clinical application

摘要:

目的 总结依维莫司的药理作用，探讨其单独或联合治疗女性生殖器常见恶性肿瘤的效果，为晚期和复发转移的患者提供新的治疗思路。方法 检索PubMed、Medline、中国知网、万方数据库、维普数据库有关依维莫司治疗子宫颈癌、卵巢癌和子宫内膜癌的相关文献，并结合临床现状对其进行综述。结果 依维莫司能够通过多种途径阻碍肿瘤细胞的生长、代谢以及肿瘤新生血管形成等，起到抗肿瘤作用。尤其当依维莫司联合化疗、放疗、激素治疗和其他分子靶向药物时，有望克服肿瘤的耐药性，提高对肿瘤治疗的敏感性。结论 依维莫司在晚期和复发转移的女性生殖器恶性肿瘤治疗中前景可观，对于提高患者预后具有很大的潜力。

Abstract:

OBJECTIVE To summarize the pharmacological mechanism of everolimus and to explore the effect of monotherapy or combined therapy of malignant tumors of female genital organs, and to provide a novel therapeutic ideas for patients with advanced stage, recurrence and metastasis. METHODS Retrieval of relevant literatures published in PubMed, Medline, CNKI, Wanfang and VIP databases on everolimus in the treatment of cervical cancer, ovarian cancer and endometrial cancer was conducted, and the current clinical situation was reviewed. RESULTS Everolimus can inhibit the growth, metabolism and angiogenesis of tumor cells through various ways, which plays a significant role in antitumor effects. Everolimus may overcome drug resistance and enhance tumor sensitivity to treatment, especially when combined with chemotherapy, radiotherapy, hormone therapy and other molecular targeted drugs. CONCLUSION Everolimus has promising prospects in advanced as well as advanced stage, recurrent and metastatic malignant tumors of female genital organs, with a great potential for improving patients’ clinical outcomes.